Japanese Journal of Ophthalmology

, Volume 54, Issue 6, pp 565–570

Intravitreal bevacizumab for age-related macular degeneration with good visual acuity

Clinical Investigation

Abstract

Purpose

To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA).

Methods

Fifteen eyes of 15 patients (mean age, 69.0 ± 11.3 years) with AMD whose VA was 0.6 or better were treated with IVB 1.25 mg/0.05 ml. The patients were followed for 12 to 29 months (mean, 17.4 ± 4.9 months).

Results

Best-corrected visual acuity (BCVA) ranged from 0.6 to 1.2 (mean, 0.89 ± 0.21) at baseline and was stable in 13 of 15 eyes (86.7%) when BCVA was 0.6 or better at the end of follow-up. The VA levels did not differ significantly (P = 0.42; paired t test) between baseline and the final examination. Two of the 15 eyes underwent photodynamic therapy during follow-up. The mean central retinal thickness significantly decreased from 278.4 ± 71.9 μm at baseline to 240.00 ± 58.5 μm at 3 months after the first IVB treatment (P = 0.02; Wilcoxon signed rank test). During follow-up, a mean of two injections was administered, and 47% of patients required only one injection. No adverse events developed.

Conclusion

IVB was effective for maintaining good vision in exudative AMD in 15 eyes for at least 12 months.

Keywords

age-related macular degeneration anti-VEGF therapy choroidal neovascularization good visual acuity intravitreal bevacizumab injection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese Age-Related Macular Degeneration Trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1049–1061.CrossRefGoogle Scholar
  2. 2.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329–1345.Google Scholar
  3. 3.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198–207.Google Scholar
  4. 4.
    Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541–560.CrossRefGoogle Scholar
  5. 5.
    Treatment of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol 2003;136:407–418.CrossRefGoogle Scholar
  6. 6.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, and Verteporfin in Photodynamic Therapy (VIP) Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials—TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683–696.CrossRefGoogle Scholar
  7. 7.
    Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.CrossRefPubMedGoogle Scholar
  8. 8.
    VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, Chakravathy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508–1521.Google Scholar
  9. 9.
    Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.CrossRefPubMedGoogle Scholar
  10. 10.
    Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.CrossRefPubMedGoogle Scholar
  11. 11.
    Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912–918.Google Scholar
  12. 12.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372.CrossRefPubMedGoogle Scholar
  13. 13.
    Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saav M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular agerelated macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249–256.CrossRefPubMedGoogle Scholar
  14. 14.
    Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:1–3.CrossRefGoogle Scholar
  15. 15.
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855–859.CrossRefPubMedGoogle Scholar
  16. 16.
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179–2182CrossRefPubMedGoogle Scholar
  17. 17.
    Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246–252.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society (JOS) 2010

Authors and Affiliations

  1. 1.Department of OphthalmologyGunma University School of MedicineMaebashiJapan
  2. 2.Department of OphthalmologyGunma University School of MedicineMaebashiJapan

Personalised recommendations